Michael Smolinski - Aug 3, 2021 Form 3 Insider Report for Athenex, Inc. (ATNXQ)

Role
Chief Scientific Officer
Signature
/s/ Steven Adams, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Aug 3, 2021
Transactions value $
$0
Form type
3
Date filed
10/27/2021, 04:16 PM
Next filing
Jan 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNXQ Common Stock 5.17K Aug 3, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 1.6K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 4K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 4.2K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 4K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 6.93K $5.50 Direct
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 10K $5.50 Direct
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 10K $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 7.5K $17.30 Direct F1
holding ATNXQ Stock Option (Right to Buy) Aug 3, 2021 Common Stock 24K $10.26 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in four equal annual installments beginning on March 27, 2019.
F2 This option vests in four equal annual installments beginning on August 27, 2021.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney